請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/88585
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳振中 | zh_TW |
dc.contributor.advisor | Jerry Chun-Chung Chan | en |
dc.contributor.author | 葉貞岑 | zh_TW |
dc.contributor.author | Chen-Tsen Yeh | en |
dc.date.accessioned | 2023-08-15T16:56:42Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2023-08-15 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-07-31 | - |
dc.identifier.citation | (1) Alzheimer, A.; Stelzmann, R. A.; Schnitzlein, H. N.; Murtagh, F. R. An English Translation of Alzheimer’s 1907 Paper, “Uber Eine Eigenartige Erkankung Der Hirnrinde.” Clin. Anat. N. Y. N. 1995, 8 (6), 429–431.
(2) Cipriani, G.; Dolciotti, C.; Picchi, L.; Bonuccelli, U. Alzheimer and His Disease: A Brief History. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2011, 32 (2), 275–279. (3) Burns, A.; Iliffe, S. Alzheimer’s Disease. BMJ. 2009, 338, b158. (4) GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 310 Diseases and Injuries, 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015. Lancet Lond. Engl. 2016, 388 (10053), 1545–1602. (5) Breijyeh, Z.; Karaman, R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Mol. Basel Switz. 2020, 25 (24), 5789. (6) Yankner, B. A.; Dawes, L. R.; Fisher, S.; Villa-Komaroff, L.; Oster-Granite, M. L.; Neve, R. L. Neurotoxicity of a Fragment of the Amyloid Precursor Associated with Alzheimer’s Disease. Science. 1989, 245 (4916), 417–420. (7) Hardy, J.; Allsop, D. Amyloid Deposition as the Central Event in the Aetiology of Alzheimer’s Disease. Trends Pharmacol. Sci. 1991, 12, 383–388. (8) Hardy, J. A.; Higgins, G. A. Alzheimer’s Disease: The Amyloid Cascade Hypothesis. Science. 1992, 256 (5054), 184–185. (9) Glenner, G. G.; Wong, C. W. Alzheimer’s Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein. Biochem. Biophys. Res. Commun. 1984, 120 (3), 885–890. (10) Kang, J.; Lemaire, H. G.; Unterbeck, A.; Salbaum, J. M.; Masters, C. L.; Grzeschik, K. H.; Multhaup, G.; Beyreuther, K.; Müller-Hill, B. The Precursor of Alzheimer’s Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor. Nature. 1987, 325 (6106), 733–736. (11) O’Brien, R. J.; Wong, P. C. Amyloid Precursor Protein Processing and Alzheimer’s Disease. Annu. Rev. Neurosci. 2011, 34, 185–204. (12) Fernandez, M. A.; Biette, K.; Dolios, G.; Seth, D.; Wang, R.; Wolfe, M. S. Transmembrane Substrate Determinants for γ-Secretase Processing of APP CTFβ. Biochemistry. 2016, 55 (40), 5675–5688. (13) Chen, G.-F.; Xu, T.-H.; Yan, Y.; Zhou, Y.-R.; Jiang, Y.; Melcher, K.; Xu, H. E. Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development. Acta Pharmacol. Sin. 2017, 38 (9), 1205–1235. (14) Erten-Lyons, D.; Woltjer, R. L.; Dodge, H.; Nixon, R.; Vorobik, R.; Calvert, J. F.; Leahy, M.; Montine, T.; Kaye, J. Factors Associated with Resistance to Dementia despite High Alzheimer Disease Pathology. Neurology. 2009, 72 (4), 354–360. (15) Sloane, J. A.; Pietropaolo, M. F.; Rosene, D. L.; Moss, M. B.; Peters, A.; Kemper, T.; Abraham, C. R. Lack of Correlation between Plaque Burden and Cognition in the Aged Monkey. Acta Neuropathol. (Berl.). 1997, 94 (5), 471–478. (16) Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R. W.; Bullock, R.; Love, S.; Neal, J. W.; Zotova, E.; Nicoll, J. A. Long-Term Effects of Aβ42 Immunisation in Alzheimer’s Disease: Follow-up of a Randomised, Placebo-Controlled Phase I Trial. The Lancet. 2008, 372 (9634), 216–223. (17) Y, Z.; L, L.; J, J.; L, J.; C, G.; J, P.; Z, X.; W, Q.; R, L.; D, L.; N, P. A Lifespan Observation of a Novel Mouse Model: In Vivo Evidence Supports Aβ Oligomer Hypothesis. PloS One. 2014, 9 (1). (18) Ferreira, S. T.; Lourenco, M. V.; Oliveira, M. M.; Felice, F. G. D. Soluble Amyloid-β Oligomers as Synaptotoxins Leading to Cognitive Impairment in Alzheimer’s Disease. Front. Cell. Neurosci. 2015, 9. (19) Lambert, M. P.; Barlow, A. K.; Chromy, B. A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T. E.; Rozovsky, I.; Trommer, B.; Viola, K. L.; Wals, P.; Zhang, C.; Finch, C. E.; Krafft, G. A.; Klein, W. L. Diffusible, Nonfibrillar Ligands Derived from Aβ1–42 Are Potent Central Nervous System Neurotoxins. Proc. Natl. Acad. Sci. 1998, 95 (11), 6448–6453. (20) Shankar, G. M.; Li, S.; Mehta, T. H.; Garcia-Munoz, A.; Shepardson, N. E.; Smith, I.; Brett, F. M.; Farrell, M. A.; Rowan, M. J.; Lemere, C. A.; Regan, C. M.; Walsh, D. M.; Sabatini, B. L.; Selkoe, D. J. Amyloid-Beta Protein Dimers Isolated Directly from Alzheimer’s Brains Impair Synaptic Plasticity and Memory. Nat. Med. 2008, 14 (8), 837–842. (21) Selkoe, D. J. Alzheimer’s Disease Is a Synaptic Failure. Science. 2002, 298 (5594), 789–791. (22) Selkoe, D. J.; Hardy, J. The Amyloid Hypothesis of Alzheimer’s Disease at 25 Years. EMBO Mol. Med. 2016, 8 (6), 595–608. (23) Klein, W. L.; Krafft, G. A.; Finch, C. E. Targeting Small Aβ Oligomers: The Solution to an Alzheimer’s Disease Conundrum? Trends Neurosci. 2001, 24 (4), 219–224. (24) Ferreira, S. T.; Vieira, M. N. N.; De Felice, F. G. Soluble Protein Oligomers as Emerging Toxins in Alzheimer’s and Other Amyloid Diseases. IUBMB Life. 2007, 59 (4–5), 332–345. (25) Ferreira, S. T.; Klein, W. L. The Aβ Oligomer Hypothesis for Synapse Failure and Memory Loss in Alzheimer’s Disease. Neurobiol. Learn. Mem. 2011, 96 (4), 529–543. (26) Walsh, D. M.; Selkoe, D. J. A Beta Oligomers - a Decade of Discovery. J. Neurochem. 2007, 101 (5), 1172–1184. (27) Benilova, I.; Karran, E.; De Strooper, B. The Toxic Aβ Oligomer and Alzheimer’s Disease: An Emperor in Need of Clothes. Nat. Neurosci. 2012, 15 (3), 349–357. (28) Jin, M.; Shepardson, N.; Yang, T.; Chen, G.; Walsh, D.; Selkoe, D. J. Soluble Amyloid Beta-Protein Dimers Isolated from Alzheimer Cortex Directly Induce Tau Hyperphosphorylation and Neuritic Degeneration. Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (14), 5819–5824. (29) De Felice, F. G.; Wu, D.; Lambert, M. P.; Fernandez, S. J.; Velasco, P. T.; Lacor, P. N.; Bigio, E. H.; Jerecic, J.; Acton, P. J.; Shughrue, P. J.; Chen-Dodson, E.; Kinney, G. G.; Klein, W. L. Alzheimer’s Disease-Type Neuronal Tau Hyperphosphorylation Induced by Aβ Oligomers. Neurobiol. Aging. 2008, 29 (9), 1334–1347. (30) Deshpande, A.; Mina, E.; Glabe, C.; Busciglio, J. Different Conformations of Amyloid Beta Induce Neurotoxicity by Distinct Mechanisms in Human Cortical Neurons. J. Neurosci. Off. J. Soc. Neurosci. 2006, 26 (22), 6011–6018. (31) Hoshi, M.; Sato, M.; Matsumoto, S.; Noguchi, A.; Yasutake, K.; Yoshida, N.; Sato, K. Spherical Aggregates of Beta-Amyloid (Amylospheroid) Show High Neurotoxicity and Activate Tau Protein Kinase I/Glycogen Synthase Kinase-3beta. Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (11), 6370–6375. (32) Chimon, S.; Shaibat, M. A.; Jones, C. R.; Calero, D. C.; Aizezi, B.; Ishii, Y. Evidence of Fibril-like β-Sheet Structures in a Neurotoxic Amyloid Intermediate of Alzheimer’s β-Amyloid. Nat. Struct. Mol. Biol. 2007, 14 (12), 1157–1164. (33) Chimon, S.; Ishii, Y. Capturing Intermediate Structures of Alzheimer’s β-Amyloid, Aβ(1−40), by Solid-State NMR Spectroscopy. J. Am. Chem. Soc. 2005, 127 (39), 13472–13473. (34) Noguchi, A.; Matsumura, S.; Dezawa, M.; Tada, M.; Yanazawa, M.; Ito, A.; Akioka, M.; Kikuchi, S.; Sato, M.; Ideno, S.; Noda, M.; Fukunari, A.; Muramatsu, S.; Itokazu, Y.; Sato, K.; Takahashi, H.; Teplow, D. B.; Nabeshima, Y.; Kakita, A.; Imahori, K.; Hoshi, M. Isolation and Characterization of Patient-Derived, Toxic, High Mass Amyloid β-Protein (Aβ) Assembly from Alzheimer Disease Brains. J. Biol. Chem. 2009, 284 (47), 32895–32905. (35) Lacor, P. N.; Buniel, M. C.; Furlow, P. W.; Sanz Clemente, A.; Velasco, P. T.; Wood, M.; Viola, K. L.; Klein, W. L. Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer’s Disease. J. Neurosci. 2007, 27 (4), 796–807. (36) Bemporad, F.; Chiti, F. Protein Misfolded Oligomers: Experimental Approaches, Mechanism of Formation, and Structure-Toxicity Relationships. Chem. Biol. 2012, 19 (3), 315–327. (37) Madhu, P.; Mukhopadhyay, S. Distinct Types of Amyloid-β Oligomers Displaying Diverse Neurotoxicity Mechanisms in Alzheimer’s Disease. J. Cell. Biochem. 2021, 122 (11), 1594–1608. (38) Fani, G.; Mannini, B.; Vecchi, G.; Cascella, R.; Cecchi, C.; Dobson, C. M.; Vendruscolo, M.; Chiti, F. Aβ Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors. ACS Chem. Neurosci. 2021, 12 (4), 766–781. (39) Laurén, J.; Gimbel, D. A.; Nygaard, H. B.; Gilbert, J. W.; Strittmatter, S. M. Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-Beta Oligomers. Nature. 2009, 457 (7233), 1128–1132. (40) Magdesian, M. H.; Carvalho, M. M. V. F.; Mendes, F. A.; Saraiva, L. M.; Juliano, M. A.; Juliano, L.; Garcia-Abreu, J.; Ferreira, S. T. Amyloid-Beta Binds to the Extracellular Cysteine-Rich Domain of Frizzled and Inhibits Wnt/Beta-Catenin Signaling. J. Biol. Chem. 2008, 283 (14), 9359–9368. (41) Zhao, W.-Q.; De Felice, F. G.; Fernandez, S.; Chen, H.; Lambert, M. P.; Quon, M. J.; Krafft, G. A.; Klein, W. L. Amyloid Beta Oligomers Induce Impairment of Neuronal Insulin Receptors. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2008, 22 (1), 246–260. (42) Arevalo, M.-A.; Roldan, P. M.; Chacón, P. J.; Rodríguez-Tebar, A. Amyloid Beta Serves as an NGF-like Neurotrophic Factor or Acts as a NGF Antagonist Depending on Its Concentration. J. Neurochem. 2009, 111 (6), 1425–1433. (43) Patnaik, A.; Zagrebelsky, M.; Korte, M.; Holz, A. Signaling via the P75 Neurotrophin Receptor Facilitates Amyloid-β-Induced Dendritic Spine Pathology. Sci. Rep. 2020, 10 (1), 13322. (44) Arispe, N.; Rojas, E.; Pollard, H. B. Alzheimer Disease Amyloid Beta Protein Forms Calcium Channels in Bilayer Membranes: Blockade by Tromethamine and Aluminum. Proc. Natl. Acad. Sci. U. S. A. 1993, 90 (2), 567–571. (45) Sciacca, M. F. M.; Kotler, S. A.; Brender, J. R.; Chen, J.; Lee, D.; Ramamoorthy, A. Two-Step Mechanism of Membrane Disruption by Aβ through Membrane Fragmentation and Pore Formation. Biophys. J. 2012, 103 (4), 702–710. (46) Bode, D. C.; Baker, M. D.; Viles, J. H. Ion Channel Formation by Amyloid-Β42 Oligomers but Not Amyloid-Β40 in Cellular Membranes. J. Biol. Chem. 2017, 292 (4), 1404–1413. (47) Butterfield, D. A.; Swomley, A. M.; Sultana, R. Amyloid β-Peptide (1–42)-Induced Oxidative Stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression. Antioxid. Redox Signal. 2013, 19 (8), 823–835. (48) Takashima, A.; Noguchi, K.; Sato, K.; Hoshino, T.; Imahori, K. Tau Protein Kinase I Is Essential for Amyloid Beta-Protein-Induced Neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 1993, 90 (16), 7789–7793. (49) Kayed, R.; Sokolov, Y.; Edmonds, B.; McIntire, T. M.; Milton, S. C.; Hall, J. E.; Glabe, C. G. Permeabilization of Lipid Bilayers Is a Common Conformation-Dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases. J. Biol. Chem. 2004, 279 (45), 46363–46366. (50) Kayed, R.; Lasagna-Reeves, C. A. Molecular Mechanisms of Amyloid Oligomers Toxicity. J. Alzheimers Dis. JAD. 2013, 33 Suppl 1, S67-78. (51) Tseng, B. P.; Green, K. N.; Chan, J. L.; Blurton-Jones, M.; LaFerla, F. M. Abeta Inhibits the Proteasome and Enhances Amyloid and Tau Accumulation. Neurobiol. Aging. 2008, 29 (11), 1607–1618. (52) Manczak, M.; Anekonda, T. S.; Henson, E.; Park, B. S.; Quinn, J.; Reddy, P. H. Mitochondria Are a Direct Site of A Beta Accumulation in Alzheimer’s Disease Neurons: Implications for Free Radical Generation and Oxidative Damage in Disease Progression. Hum. Mol. Genet. 2006, 15 (9), 1437–1449. (53) Cecon, E.; Dam, J.; Luka, M.; Gautier, C.; Chollet, A.-M.; Delagrange, P.; Danober, L.; Jockers, R. Quantitative Assessment of Oligomeric Amyloid β Peptide Binding to Α7 Nicotinic Receptor. Br. J. Pharmacol. 2019, 176 (18), 3475–3488. (54) Hashimoto, T.; Serrano-Pozo, A.; Hori, Y.; Adams, K. W.; Takeda, S.; Banerji, A. O.; Mitani, A.; Joyner, D.; Thyssen, D. H.; Bacskai, B. J.; Frosch, M. P.; Spires-Jones, T. L.; Finn, M. B.; Holtzman, D. M.; Hyman, B. T. Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide. J. Neurosci. Off. J. Soc. Neurosci. 2012, 32 (43), 15181–15192. (55) Yan, S. D.; Bierhaus, A.; Nawroth, P. P.; Stern, D. M. RAGE and Alzheimer’s Disease: A Progression Factor for Amyloid-β-Induced Cellular Perturbation? J. Alzheimers Dis. JAD. 2009, 16 (4), 833–843. (56) Yan, S. S.; Chen, D.; Yan, S.; Guo, L.; Chen, J. X. RAGE Is a Key Cellular Target for Aβ-Induced Perturbation in Alzheimer’s Disease. Front. Biosci. Sch. Ed. 2012, 4, 240–250. (57) Rogers, S. L.; Doody, R. S.; Mohs, R. C.; Friedhoff, L. T. Donepezil Improves Cognition and Global Function in Alzheimer Disease: A 15-Week, Double-Blind, Placebo-Controlled Study. Donepezil Study Group. Arch. Intern. Med. 1998, 158 (9), 1021–1031. (58) Raskind, M. A.; Peskind, E. R.; Wessel, T.; Yuan, W. Galantamine in AD: A 6-Month Randomized, Placebo-Controlled Trial with a 6-Month Extension. The Galantamine USA-1 Study Group. Neurology. 2000, 54 (12), 2261–2268. (59) Zhao, J.; Nussinov, R.; Ma, B. Mechanisms of Recognition of Amyloid-β (Aβ) Monomer, Oligomer, and Fibril by Homologous Antibodies. J. Biol. Chem. 2017, 292 (44), 18325–18343. (60) Doody, R. S.; Thomas, R. G.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; Raman, R.; Sun, X.; Aisen, P. S.; Siemers, E.; Liu-Seifert, H.; Mohs, R. Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer’s Disease. N. Engl. J. Med. 2014, 370 (4), 311–321. (61) Honig, L. S.; Vellas, B.; Woodward, M.; Boada, M.; Bullock, R.; Borrie, M.; Hager, K.; Andreasen, N.; Scarpini, E.; Liu-Seifert, H.; Case, M.; Dean, R. A.; Hake, A.; Sundell, K.; Poole Hoffmann, V.; Carlson, C.; Khanna, R.; Mintun, M.; DeMattos, R.; Selzler, K. J.; Siemers, E. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease. N. Engl. J. Med. 2018, 378 (4), 321–330. (62) Meilandt, W. J.; Maloney, J. A.; Imperio, J.; Lalehzadeh, G.; Earr, T.; Crowell, S.; Bainbridge, T. W.; Lu, Y.; Ernst, J. A.; Fuji, R. N.; Atwal, J. K. Characterization of the Selective in Vitro and in Vivo Binding Properties of Crenezumab to Oligomeric Aβ. Alzheimers Res. Ther. 2019, 11, 97. (63) Söderberg, L.; Johannesson, M.; Nygren, P.; Laudon, H.; Eriksson, F.; Osswald, G.; Möller, C.; Lannfelt, L. Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease. Neurotherapeutics. 2022, 1–12. (64) Ostrowitzki, S.; Deptula, D.; Thurfjell, L.; Barkhof, F.; Bohrmann, B.; Brooks, D. J.; Klunk, W. E.; Ashford, E.; Yoo, K.; Xu, Z.-X.; Loetscher, H.; Santarelli, L. Mechanism of Amyloid Removal in Patients with Alzheimer Disease Treated with Gantenerumab. Arch. Neurol. 2012, 69 (2), 198–207. (65) Roche - Doing now what patients need next. https://www.roche.com/media/releases/med-cor-2022-11-14 (66) Day, G. S.; Scarmeas, N.; Dubinsky, R.; Coerver, K.; Mostacero, A.; West, B.; Wessels, S. R.; Armstrong, M. J. Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee. Neurology. 2022, 98 (15), 619–631. (67) Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P. H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; O’Gorman, J.; Qian, F.; Arastu, M.; Li, M.; Chollate, S.; Brennan, M. S.; Quintero-Monzon, O.; Scannevin, R. H.; Arnold, H. M.; Engber, T.; Rhodes, K.; Ferrero, J.; Hang, Y.; Mikulskis, A.; Grimm, J.; Hock, C.; Nitsch, R. M.; Sandrock, A. The Antibody Aducanumab Reduces Aβ Plaques in Alzheimer’s Disease. Nature. 2016, 537 (7618), 50–56. (68) van Dyck, C. H.; Swanson, C. J.; Aisen, P.; Bateman, R. J.; Chen, C.; Gee, M.; Kanekiyo, M.; Li, D.; Reyderman, L.; Cohen, S.; Froelich, L.; Katayama, S.; Sabbagh, M.; Vellas, B.; Watson, D.; Dhadda, S.; Irizarry, M.; Kramer, L. D.; Iwatsubo, T. Lecanemab in Early Alzheimer’s Disease. N. Engl. J. Med. 2023, 388 (1), 9–21. (69) Goure, W. F.; Krafft, G. A.; Jerecic, J.; Hefti, F. Targeting the Proper Amyloid-Beta Neuronal Toxins: A Path Forward for Alzheimer’s Disease Immunotherapeutics. Alzheimers Res. Ther. 2014, 6 (4), 42. (70) Iannuzzi, C.; Irace, G.; Sirangelo, I. The Effect of Glycosaminoglycans (GAGs) on Amyloid Aggregation and Toxicity. Molecules. 2015, 20 (2), 2510–2528. (71) Sahoo, B. R.; Genjo, T.; Bekier, M.; Cox, S. J.; Stoddard, A. K.; Ivanova, M.; Yasuhara, K.; Fierke, C. A.; Wang, Y.; Ramamoorthy, A. Alzheimer’s Amyloid-Beta Intermediates Generated by Polymer-Nanodiscs. Chem. Commun. Camb. Engl. 2018, 54 (91), 12883–12886. (72) Scheidt, H. A.; Morgado, I.; Huster, D. Solid-State NMR Reveals a Close Structural Relationship between Amyloid-β Protofibrils and Oligomers. J. Biol. Chem. 2012, 287 (27), 22822–22826. (73) Hoyer, W.; Grönwall, C.; Jonsson, A.; Ståhl, S.; Härd, T. Stabilization of a Beta-Hairpin in Monomeric Alzheimer’s Amyloid-Beta Peptide Inhibits Amyloid Formation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (13), 5099–5104. (74) Miller, Y.; Ma, B.; Nussinov, R. Zinc Ions Promote Alzheimer Abeta Aggregation via Population Shift of Polymorphic States. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (21), 9490–9495. (75) Sandberg, A.; Luheshi, L. M.; Söllvander, S.; Pereira de Barros, T.; Macao, B.; Knowles, T. P. J.; Biverstål, H.; Lendel, C.; Ekholm-Petterson, F.; Dubnovitsky, A.; Lannfelt, L.; Dobson, C. M.; Härd, T. Stabilization of Neurotoxic Alzheimer Amyloid-Beta Oligomers by Protein Engineering. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (35), 15595–15600. (76) Härd, T. Protein Engineering to Stabilize Soluble Amyloid β-Protein Aggregates for Structural and Functional Studies. FEBS J. 2011, 278 (20), 3884–3892. (77) Klein, W. L. Aβ Toxicity in Alzheimer’s Disease: Globular Oligomers (ADDLs) as New Vaccine and Drug Targets. Neurochem. Int. 2002, 41 (5), 345–352. (78) Ahmed, M.; Davis, J.; Aucoin, D.; Sato, T.; Ahuja, S.; Aimoto, S.; Elliott, J. I.; Van Nostrand, W. E.; Smith, S. O. Structural Conversion of Neurotoxic Amyloid-β(1–42) Oligomers to Fibrils. Nat. Struct. Mol. Biol. 2010, 17 (5), 561–567. (79) Yang, C.-I.; Tsai, B. N. F.; Huang, S.-J.; Wang, T.-Y.; Tai, H.-C.; Chan, J. C. C. Aggregation of Beta-Amyloid Peptides Proximal to Zwitterionic Lipid Bilayers. Chem. Asian J. 2015, 10 (9), 1967–1971. (80) Lin, Y.-L.; Cheng, Y.-S.; Ho, C.-I.; Guo, Z.-H.; Huang, S.-J.; Org, M.-L.; Oss, A.; Samoson, A.; Chan, J. C. C. Preparation of Fibril Nuclei of Beta-Amyloid Peptides in Reverse Micelles. Chem. Commun. 2018, 54 (74), 10459–10462. (81) Chang, H.-W.; Ma, H.-I.; Wu, Y.-S.; Lee, M.-C.; Yuan, E. C.-Y.; Huang, S.-J.; Cheng, Y.-S.; Wu, M.-H.; Tu, L.-H.; Chan, J. C. C. Site Specific NMR Characterization of Abeta-40 Oligomers Cross Seeded by Abeta-42 Oligomers. Chem. Sci. 2022, 13 (29), 8526–8535. (82) Luisi, P. L. Enzymes Hosted in Reverse Micelles in Hydrocarbon Solution. Angew. Chem. Int. Ed. Engl. 1985, 24 (6), 439–450. (83) Matzke, S. F.; Creagh, A. L.; Haynes, C. A.; Prausnitz, J. M.; Blanch, H. W. Mechanisms of Protein Solubilization in Reverse Micelles. Biotechnol. Bioeng. 1992, 40 (1), 91–102. (84) Chatenay, D.; Urbach, W.; Cazabat, A. M.; Vacher, M.; Waks, M. Proteins in Membrane Mimetic Systems. Insertion of Myelin Basic Protein into Microemulsion Droplets. Biophys. J. 1985, 48 (6), 893–898. (85) Tonova, K.; Lazarova, Z. Reversed Micelle Solvents as Tools of Enzyme Purification and Enzyme-Catalyzed Conversion. Biotechnol. Adv. 2008, 26 (6), 516–532. (86) Sharon, M.; Modi, F.; Sharon, M.; Sharon, M.; Modi, F.; Sharon, M. Titania Based Nanocomposites as a Photocatalyst: A Review. AIMS Mater. Sci. 2016, 3 (3), 1236–1254. (87) Paul, B. K.; Mitra, R. K. Water Solubilization Capacity of Mixed Reverse Micelles: Effect of Surfactant Component, the Nature of the Oil, and Electrolyte Concentration. J. Colloid Interface Sci. 2005, 288 (1), 261–279. (88) Nazário, L. M. M.; Hatton, T. A.; Crespo, J. P. S. G. Nonionic Cosurfactants in AOT Reversed Micelles: Effect on Percolation, Size, and Solubilization Site. Langmuir. 1996, 12 (26), 6326–6335. (89) Lemyre, J.-L.; Lamarre, S.; Beaupré, A.; Ritcey, A. M. A New Approach for the Characterization of Reverse Micellar Systems by Dynamic Light Scattering. Langmuir. 2010, 26 (13), 10524–10531. (90) Küchler, A.; Yoshimoto, M.; Luginbühl, S.; Mavelli, F.; Walde, P. Enzymatic Reactions in Confined Environments. Nat. Nanotechnol. 2016, 11 (5), 409–420. (91) Liu, Y.; Goebl, J.; Yin, Y. Templated Synthesis of Nanostructured Materials. Chem. Soc. Rev. 2013, 42 (7), 2610–2653. (92) Arsene, M.-L.; Răut, I.; Călin, M.; Jecu, M.-L.; Doni, M.; Gurban, A.-M. Versatility of Reverse Micelles: From Biomimetic Models to Nano (Bio)Sensor Design. Processes. 2021, 9 (2), 345. (93) Schägger, H. Tricine–SDS-PAGE. Nat. Protoc. 2006, 1 (1), 16–22. (94) onlinemicrobiologynote. SDS-PAGE - Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (PAGE). https://microbiologynote.com/sds-page/ (95) Hillenkamp, F.; Karas, M.; Beavis, R. C.; Chait, B. T. Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry of Biopolymers. Anal. Chem. 1991, 63 (24), 1193A-1203A. (96) Tanaka, K.; Waki, H.; Ido, Y.; Akita, S.; Yoshida, Y.; Yoshida, T.; Matsuo, T. Protein and Polymer Analyses up to m/z 100 000 by Laser Ionization Time-of-Flight Mass Spectrometry. Rapid Commun. Mass Spectrom. 1988, 2 (8), 151–153. (97) Croxatto, A.; Prod’hom, G.; Greub, G. Applications of MALDI-TOF Mass Spectrometry in Clinical Diagnostic Microbiology. FEMS Microbiol. Rev. 2012, 36 (2), 380–407. (98) van der Loop, T. H.; Panman, M. R.; Lotze, S.; Zhang, J.; Vad, T.; Bakker, H. J.; Sager, W. F. C.; Woutersen, S. Structure and Dynamics of Water in Nonionic Reverse Micelles: A Combined Time-Resolved Infrared and Small Angle x-Ray Scattering Study. J. Chem. Phys. 2012, 137 (4), 044503. (99) Lipgens, S.; Schübel, D.; Schlicht, L.; Spilgies, J.-H.; Ilgenfritz, G.; Eastoe, J.; Heenan, R. K. Percolation in Nonionic Water-in-Oil−Microemulsion Systems: A Small Angle Neutron Scattering Study. Langmuir. 1998, 14 (5), 1041–1049. (100) Lemyre, J.-L.; Ritcey, A. M. Characterization of a Reverse Micellar System by 1H NMR. Langmuir. 2010, 26 (9), 6250–6255. (101) Chandradass, J.; Jadhav, A. H.; Kim, H. Surfactant Modified MgFe2O4 Nanopowders by Reverse Micelle Processing: Effect of Water to Surfactant Ratio (R) on the Particle Size and Magnetic Property. Appl. Surf. Sci. 2012, 258 (7), 3315–3320. (102) Mathew, D. S.; Juang, R.-S. Improved Back Extraction of Papain from AOT Reverse Micelles Using Alcohols and a Counter-Ionic Surfactant. Biochem. Eng. J. 2005, 25 (3), 219–225. (103) Jarudilokkul, S.; Poppenborg, L. H.; Stuckey, D. C. Backward Extraction of Reverse Micellar Encapsulated Proteins Using a Counterionic Surfactant. Biotechnol. Bioeng. 1999, 62 (5), 593–601. (104) Nishiki, T.; Muto, A.; Kataoka, T.; Kato, D. Back Extraction of Proteins from Reversed Micellar to Aqueous Phase: Partitioning Behaviour and Enrichment. Chem. Eng. J. Biochem. Eng. J. 1995, 59 (3), 297–301. (105) Lee, M.-C.; Yu, W.-C.; Shih, Y.-H.; Chen, C.-Y.; Guo, Z.-H.; Huang, S.-J.; Chan, J. C. C.; Chen, Y.-R. Zinc Ion Rapidly Induces Toxic, off-Pathway Amyloid-β Oligomers Distinct from Amyloid-β Derived Diffusible Ligands in Alzheimer’s Disease. Sci. Rep. 2018, 8 (1), 4772. (106) Aminabhavi, T. M.; Patil, V. B.; Aralaguppi, M. I.; Phayde, H. T. S. Density, Viscosity, and Refractive Index of the Binary Mixtures of Cyclohexane with Hexane, Heptane, Octane, Nonane, and Decane at (298.15, 303.15, and 308.15) K. J. Chem. Eng. Data. 1996, 41 (3), 521–525. (107) Khurana, R.; Coleman, C.; Ionescu-Zanetti, C.; Carter, S. A.; Krishna, V.; Grover, R. K.; Roy, R.; Singh, S. Mechanism of Thioflavin T Binding to Amyloid Fibrils. J. Struct. Biol. 2005, 151 (3), 229–238. (108) Wolfe, L. S.; Calabrese, M. F.; Nath, A.; Blaho, D. V.; Miranker, A. D.; Xiong, Y. Protein-Induced Photophysical Changes to the Amyloid Indicator Dye Thioflavin T. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (39), 16863–16868. (109) LeVine, H. Quantification of Beta-Sheet Amyloid Fibril Structures with Thioflavin T. Methods Enzymol. 1999, 309, 274–284. (110) Brenner, S.; Horne, R. W. A Negative Staining Method for High Resolution Electron Microscopy of Viruses. Biochim. Biophys. Acta. 1959, 34, 103–110. (111) De Carlo, S.; Harris, J. R. Negative Staining and Cryo-Negative Staining of Macromolecules and Viruses for TEM. Micron Oxf. Engl. 1993. 2011, 42 (2), 117–131. (112) 电子显微镜拍出细胞彩照_百科TA说. https://baike.baidu.com/tashuo/browse/content?id=5c9384dc4fdaa52f52359f65 (113) Isabell, T. C.; Fischione, P. E.; O’Keefe, C.; Guruz, M. U.; Dravid, V. P. Plasma Cleaning and Its Applications for Electron Microscopy. Microsc. Microanal. Off. J. Microsc. Soc. Am. Microbeam Anal. Soc. Microsc. Soc. Can. 1999, 5 (2), 126–135. (114) González-Pinzón, R.; Haggerty, R.; Myrold, D. D. Measuring Aerobic Respiration in Stream Ecosystems Using the Resazurin-Resorufin System. J. Geophys. Res. Biogeosciences. 2012, 117 (G3). (115) Silanikove, N.; Shapiro, F. CHAPTER 23. Combined Assays for Lactose and Galactose by Enzymatic Reactions. Food and Nutritional Components in Focus. Royal Society of Chemistry: Cambridge, 2012, pp 395–404. (116) Anoopkumar-Dukie, S.; Carey, J. B.; Conere, T.; O’sullivan, E.; van Pelt, F. N.; Allshire, A. Resazurin Assay of Radiation Response in Cultured Cells. Br. J. Radiol. 2005, 78 (934), 945–947. (117) Riss, T. L.; Moravec, R. A.; Niles, A. L.; Duellman, S.; Benink, H. A.; Worzella, T. J.; Minor, L. Cell Viability Assays. Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences: Bethesda (MD), 2004 (118) Braut-Boucher, F.; Aubery, M. Fluorescent Molecular Probes. Encyclopedia of Spectroscopy and Spectrometry (Third Edition). Academic Press: Oxford, 2017, pp 661–669. (119) Tsai, T. W. T.; Chan, J. C. C. Chapter 1 - Recent Progress in the Solid-State NMR Studies of Biomineralization. Annual Reports on NMR Spectroscopy. Academic Press, 2011, Vol. 73, pp 1–61. (120) Petkova, A. T.; Ishii, Y.; Balbach, J. J.; Antzutkin, O. N.; Leapman, R. D.; Delaglio, F.; Tycko, R. A Structural Model for Alzheimer’s Beta -Amyloid Fibrils Based on Experimental Constraints from Solid State NMR. Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (26), 16742–16747. (121) Andrew, E. R.; Bradbury, A.; Eades, R. G. Nuclear Magnetic Resonance Spectra from a Crystal Rotated at High Speed. Nature. 1958, 182 (4650), 1659–1659. (122) Lowe, I. J. Free Induction Decays of Rotating Solids. Phys. Rev. Lett. 1959, 2 (7), 285–287. (123) Bhusnure, Dr. O. Advanced Approaches in Solid-State Analysis of Pharmaceuticals. Int. J. Pharm. Pharmacutical Res. 2016, 5, 1–29. (124) Pines, A.; Gibby, M.; Waugh, J. Proton-Enhanced Dilute Spins in Solid. J. Chem. Phys. 1973, 59. (125) Dudek, M. K.; Kaźmierski, S.; Potrzebowski, M. J. Chapter Three - Fast and Very Fast MAS Solid State NMR Studies of Pharmaceuticals. Annual Reports on NMR Spectroscopy. Academic Press, 2021, Vol. 103, pp 97–189. (126) Takegoshi, K.; Nakamura, S.; Terao, T. 13C–1H Dipolar-Assisted Rotational Resonance in Magic-Angle Spinning NMR. Chem. Phys. Lett. 2001, 344 (5), 631–637. (127) Takegoshi, K.; Shinji, N.; Terao, T. 13C-1H Dipolar-Driven 13C-13C Recoupling without 13C Rf Irradiation in Nuclear Magnetic Resonance of Rotating Solids. Chem. Phys. - CHEM PHYS. 2003, 118, 2325–2341. (128) Holland, G. P.; Creager, M. S.; Jenkins, J. E.; Lewis, R. V.; Yarger, J. L. Determining Secondary Structure in Spider Dragline Silk by Carbon−Carbon Correlation Solid-State NMR Spectroscopy. J. Am. Chem. Soc. 2008, 130 (30), 9871–9877. (129) Wang, Y.; Jardetzky, O. Probability-Based Protein Secondary Structure Identification Using Combined NMR Chemical-Shift Data. Protein Sci. Publ. Protein Soc. 2002, 11 (4), 852–861. (130) Gremer, L.; Schölzel, D.; Schenk, C.; Reinartz, E.; Labahn, J.; Ravelli, R. B. G.; Tusche, M.; Lopez-Iglesias, C.; Hoyer, W.; Heise, H.; Willbold, D.; Schröder, G. F. Fibril Structure of Amyloid-β(1–42) by Cryo–Electron Microscopy. Science. 2017, 358 (6359), 116–119. (131) Meisl, G.; Kirkegaard, J. B.; Arosio, P.; Michaels, T. C. T.; Vendruscolo, M.; Dobson, C. M.; Linse, S.; Knowles, T. P. J. Molecular Mechanisms of Protein Aggregation from Global Fitting of Kinetic Models. Nat. Protoc. 2016, 11 (2), 252–272. (132) Cohen, S. I. A.; Linse, S.; Luheshi, L. M.; Hellstrand, E.; White, D. A.; Rajah, L.; Otzen, D. E.; Vendruscolo, M.; Dobson, C. M.; Knowles, T. P. J. Proliferation of Amyloid-Β42 Aggregates Occurs through a Secondary Nucleation Mechanism. Proc. Natl. Acad. Sci. 2013, 110 (24), 9758–9763. (133) Meisl, G.; Yang, X.; Hellstrand, E.; Frohm, B.; Kirkegaard, J. B.; Cohen, S. I. A.; Dobson, C. M.; Linse, S.; Knowles, T. P. J. Differences in Nucleation Behavior Underlie the Contrasting Aggregation Kinetics of the Aβ40 and Aβ42 Peptides. Proc. Natl. Acad. Sci. 2014, 111 (26), 9384–9389. (134) Shen, Y.; Bax, A. Protein Structural Information Derived from NMR Chemical Shift with the Neural Network Program TALOS-N. Methods Mol. Biol. Clifton NJ. 2015, 1260, 17–32. (135) Yang, Y.; Arseni, D.; Zhang, W.; Huang, M.; Lövestam, S.; Schweighauser, M.; Kotecha, A.; Murzin, A. G.; Peak-Chew, S. Y.; Macdonald, J.; Lavenir, I.; Garringer, H. J.; Gelpi, E.; Newell, K. L.; Kovacs, G. G.; Vidal, R.; Ghetti, B.; Ryskeldi-Falcon, B.; Scheres, S. H. W.; Goedert, M. Cryo-EM Structures of Amyloid-β 42 Filaments from Human Brains. Science. 2022, 375 (6577), 167–172. (136) Vadukul, D. M.; Maina, M.; Franklin, H.; Nardecchia, A.; Serpell, L. C.; Marshall, K. E. Internalisation and Toxicity of Amyloid-β 1-42 Are Influenced by Its Conformation and Assembly State Rather than Size. FEBS Lett. 2020, 594 (21), 3490–3503. (137) Scheidt, H. A.; Das, A.; Korn, A.; Krueger, M.; Maiti, S.; Huster, D. Structural Characteristics of Oligomers Formed by Pyroglutamate-Modified Amyloid β Peptides Studied by Solid-State NMR. Phys. Chem. Chem. Phys. 2020, 22 (29), 16887–16895. (138) Lu, J.-X.; Qiang, W.; Yau, W.-M.; Schwieters, C. D.; Meredith, S. C.; Tycko, R. Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue. Cell. 2013, 154 (6), 1257–1268. (139) Walsh, D. M.; Lomakin, A.; Benedek, G. B.; Condron, M. M.; Teplow, D. B. Amyloid Beta-Protein Fibrillogenesis. Detection of a Protofibrillar Intermediate. J. Biol. Chem. 1997, 272 (35), 22364–22372. (140) Bitan, G.; Lomakin, A.; Teplow, D. B. Amyloid β-Protein Oligomerization: PRENUCLEATION INTERACTIONS REVEALED BY PHOTO-INDUCED CROSS-LINKING OF UNMODIFIED PROTEINS*. J. Biol. Chem. 2001, 276 (37), 35176–35184. (141) Chen, W.-T.; Hong, C.-J.; Lin, Y.-T.; Chang, W.-H.; Huang, H.-T.; Liao, J.-Y.; Chang, Y.-J.; Hsieh, Y.-F.; Cheng, C.-Y.; Liu, H.-C.; Chen, Y.-R.; Cheng, I. H. Amyloid-Beta (Aβ) D7H Mutation Increases Oligomeric Aβ42 and Alters Properties of Aβ-Zinc/Copper Assemblies. PLOS ONE. 2012, 7 (4), e35807. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/88585 | - |
dc.description.abstract | 阿茲海默症是一種神經退化性疾病,早期研究認為在大腦中堆積的乙型類澱粉蛋白 (Aβ) 斑塊是造成阿茲海默症的成因,近年來則有研究顯示出Aβ寡聚物具有神經細胞毒性,並且對於神經突觸造成傷害。最新設計的單克隆抗體Lecanemab,結合可溶性Aβ聚集體的能力遠大於單體及纖維,相較於過去偏好結合纖維或單體的抗體,Lecanemab能夠更有效減少患者腦中的斑塊沉積以及減緩認知退化,顯示出Aβ寡聚物為靶向治療關鍵,因此Aβ寡聚物為此論文的研究重點。但因為Aβ會快速聚集形成纖維的特性,在過去的文獻中很難對Aβ寡聚物進行系統性研究,至今仍沒有研究指出寡聚物的毒性與結構之間的關係,也無法了解實際的致病機制。
過去本實驗室以cyclohexane/CO520/NH4OAc三相系統組成的逆相微胞製備出23 nm Aβ40寡聚物,命名為RM23-Aβ40,本研究將油相改為使用1:1混合的n-hexane及cyclohexane,再進一步調整界面活性劑濃度以及水跟界面活性劑的比例,製備出10 nm的逆相微胞,將Aβ40單體限制於10 nm逆相微胞中,透過微胞間的碰撞使得微胞內單體聚集形成Aβ40寡聚物。利用穿透式電子顯微鏡拍攝從10 nm逆相微胞中反萃出的Aβ40寡聚物,命名為RM10-Aβ40,後續利用ImageJ批次定量分析Aβ40寡聚物平均直徑為8.7 ± 2.8 nm,再使用硫磺素 (ThT) 螢光分析,顯示出RM10-Aβ40會自聚集形成纖維且有一段RM23-Aβ40沒有的延滯期,代表RM10-Aβ40需經過結構的轉變才能形成纖維,顯示出RM10-Aβ40與RM23-Aβ40為纖維化過程中不同階段的蛋白質寡聚物,且RM10-Aβ40為較小較早期的Aβ40寡聚物。再藉由alamarBlue assay比較兩種寡聚物的細胞毒性,結果顯示RM10-Aβ40相較於RM23-Aβ40具有更高的毒性,可能是造成阿茲海默症的關鍵蛋白。為了瞭解RM10-Aβ40的結構資訊,我們使用固態核磁共振進行測量。結果顯示RM23-Aβ40和RM10-Aβ40整體的化學位移及半峰全寬大約相同,但從訊號強度分析顯示出RM10-Aβ40的帶電荷殘基動態變化程度高於RM23-Aβ40,推測殘基高度動態變化可能是影響細胞毒性及纖維化過程的關鍵。本研究比較了不同大小Aβ40寡聚物毒性與結構差異,推測Aβ40寡聚物的殘基動態變化程度與細胞毒性可能更具相關性。 | zh_TW |
dc.description.abstract | Alzheimer's disease (AD) is a neurodegenerative disease. Early research suggested that the accumulation of beta-amyloid (Aβ) protein plaques in the brain was the cause of AD. However, recent studies have shown that Aβ oligomers have neurotoxicity and impair synaptic function. The latest monoclonal antibody, Lecanemab, designed to bind the soluble Aβ aggregates, is more effective in reducing brain Aβ plaques and slowing cognitive decline compared to previous antibodies, which preferentially bind to fibrils or monomers. This demonstrates that targeting Aβ oligomers is crucial to curing AD. Therefore, Aβ oligomers are the current focus of research. However, due to the characteristic of Aβ rapidly aggregating to form fibers, it has been difficult to study Aβ oligomers in the past. To date, no studies have identified the relationship between the toxicity and structure of Aβ oligomers.
In the past, we prepared 23 nm Aβ40 oligomers using a reverse micelle (RM) system composed of a cyclohexane/CO520/NH4OAc ternary system, which we called RM23-Aβ40. In this study, we changed the organic phase to a 1:1 mixture of n-hexane and cyclohexane and further adjusted the surfactant concentration and the water to surfactant ratio for the preparation of 10-nm RMs. The Aβ40 monomers were confined to the RMs and aggregated to form Aβ40 oligomers through collisions between micelles. Transmission electron microscopy (TEM) images showed the morphology of the Aβ40 oligomers extracted from the 10-nm RMs, which we named RM10-Aβ40. Then we used ImageJ to quantitative the size was 8.7 ± 2.8 nm. Subsequently, thioflavin T (ThT) fluorescence analysis showed that RM10-Aβ40 can self-aggregate to form fibers and had a lag phase that RM23-Aβ40 did not have. This indicates that RM10-Aβ40 needs structural transformation to form fibers, while RM23-Aβ40 can form fibers without structural transformation. It showed that RM10-Aβ40 and RM23-Aβ40 are Aβ40 oligomers at different stages of the fibrillization process, and RM10-Aβ40 is at the early stage. From the results of alamarBlue assay, we observed that the cytotoxicity of RM10-Aβ40 was higher than RM23-Aβ40, indicating that it may be a crucial species contributing to AD. To further investigate their structural information, we carried out solid-state NMR measurements on 13C labeled RM10-Aβ40. Even though the overall line widths and chemical shifts of the RM10-Aβ40 and RM23-Aβ40 were comparable, intensity analysis revealed a higher degree of motional dynamic in charged residues of RM10-Aβ40 than in RM23-Aβ40. This study directly compared the cytotoxicity and structural differences between different size of Aβ40 oligomers. Overall, we suggest that the motional dynamics might have stronger correlation with cytotoxicity. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-08-15T16:56:42Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-08-15T16:56:42Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 口試委員審定書 I
謝誌 II 中文摘要 VII Abstract IX 縮寫表 XI 目錄 XIII 圖目錄 XVI 表目錄 XIX 第一章 緒論 1 1.1 乙型類澱粉蛋白與阿茲海默症的關係 1 1.1.1 阿茲海默症 1 1.1.2 乙型類澱粉蛋白 2 1.2 乙型類澱粉蛋白寡聚物 5 1.2.1 寡聚物種類及大小 5 1.2.2 寡聚物的致病機制 9 1.2.3 藥物發展 11 1.2.4 過去培養Aβ寡聚物之方法 13 1.3 逆相微胞簡介 16 1.4 研究動機 21 第二章 實驗技術與樣品製備 22 2.1 化學藥品及使用儀器 22 2.1.1 化學藥品 22 2.1.2 使用儀器 24 2.2 胜肽製備 26 2.2.1 蛋白表達 27 2.2.2 蛋白純化 28 2.2.3 胜肽鑑定 30 2.3 使用逆相微胞製備小尺寸Aβ寡聚物 33 2.3.1 Aβ單體製備 33 2.3.2 小尺寸逆相微胞製備及培養Aβ寡聚物 34 2.3.3 反向萃取Aβ寡聚物 34 2.3.4 Aβ40與CO520的反萃效率鑑定 35 2.4 鑑定方法 36 2.4.1 動態光散射粒徑分析 36 2.4.2 斑點印跡法 37 2.4.3 硫黃素螢光分析 38 2.4.4 穿透式電子顯微鏡 39 2.4.5 ImageJ 40 2.4.6 阿爾瑪藍細胞存活試驗 41 2.4.7 固態核磁共振光譜 44 第三章 以逆相微胞製備Aβ寡聚物 51 3.1 純化Aβ胜肽及鑑定 51 3.2 以逆相微胞製備小尺寸Aβ寡聚物 53 3.2.1 逆相微胞製備Aβ寡聚物及穩定度鑑定 53 3.2.2 蛋白質反萃效率及CO520殘留量之鑑定 54 3.2.3 RM10-Aβ40寡聚物尺寸鑑定 56 3.3 RM10-Aβ40性質鑑定 58 3.3.1 RM10-Aβ40自聚集 58 3.3.2 RM10-Aβ40毒性鑑定 64 3.4 RM10-Aβ40結構資訊 68 3.4.1 RM10-Aβ40化學位移 69 3.4.2 RM10-Aβ40訊號強度 75 3.5 章節總結 77 第四章 結論與未來展望 78 4.1 論文總結 78 4.2 未來展望 78 參考文獻 80 附錄 93 附錄 A 小尺寸逆相微胞比例最佳化測試條件 93 附錄 B 逆相微胞內蛋白質濃度測試條件 95 附錄 C 反萃方法測試 96 附錄 D 23 nm寡聚物製備及反萃效率計算 97 附錄 E PICUP光交聯反應固定寡聚物 99 附錄 F 細胞存活率分析 (MTT assay) 實驗結果 102 附錄 G 以S1–S4製備的RM10-Aβ40的NMR數據 104 | - |
dc.language.iso | zh_TW | - |
dc.title | 以逆相微胞控制乙型類澱粉蛋白寡聚物大小並探討其細胞毒性及結構差異 | zh_TW |
dc.title | Size control of Aβ40 oligomers by reverse micelles and study of their difference in cytotoxicity and structure | en |
dc.type | Thesis | - |
dc.date.schoolyear | 111-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 戴桓青;黃人則 | zh_TW |
dc.contributor.oralexamcommittee | Hwan-Ching Tai;Jen-Tse Huang | en |
dc.subject.keyword | 乙型類澱粉蛋白寡聚物,逆相微胞,細胞毒性,動態變化,固態核磁共振, | zh_TW |
dc.subject.keyword | Aβ oligomers,reverse micelle,cytotoxicity,motional dynamics,solid-state NMR, | en |
dc.relation.page | 108 | - |
dc.identifier.doi | 10.6342/NTU202302296 | - |
dc.rights.note | 同意授權(限校園內公開) | - |
dc.date.accepted | 2023-08-02 | - |
dc.contributor.author-college | 理學院 | - |
dc.contributor.author-dept | 化學系 | - |
顯示於系所單位: | 化學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf 授權僅限NTU校內IP使用(校園外請利用VPN校外連線服務) | 7.69 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。